This article is intended for primary care clinicians, obstetricians/gynecologists, nurses, pharmacists, infectious disease experts, pulmonologists, and other members of the healthcare team involved in breastfeeding support and postpartum care for women with coronavirus disease (COVID-19) and their offspring.
The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.
Upon completion of this activity, participants will be able to:
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credit for learning and change.
Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; none of these credits is in the area of pharmacology.
Medscape, LLC designates this continuing education activity for 0.50 contact hour(s) (0.05 CEUs) (Universal Activity Number JA0007105-0000-20-053-H01-P).
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / CE Released: 4/24/2020
Valid for credit through: 4/24/2021, 11:59 PM EST
processing....
Note: This is the seventeenth of a series of clinical briefs on the coronavirus outbreak. The information on this subject is continually evolving. The content within this activity serves as a historical reference to the information that was available at the time of this publication. We continue to add to the collection of activities on this subject as new information becomes available.
The COVID-19 pandemic continues to take its toll worldwide, with exponential increases in cases and deaths affecting nearly all countries. Transmission via respiratory droplets released during a cough or sneeze appears to be the primary route, but virus has also been identified in the feces and has been shown to survive on surfaces for periods of up to several days. Persons at highest risk of becoming infected with SARS-CoV-2 appear to be individuals in close, prolonged contact with persons with COVID-19, even though the latter may still be asymptomatic or have experienced clinical recovery.
Given the above considerations, postpartum contact with and breastfeeding of an infant born to a mother with COVID-19 may present clear risks. Counterbalancing these risks are the known benefits to mother and child of close contact and breastfeeding. Different organizations, countries, and experts vary in how they calculate this balance.
Breastfeeding decisions for women with COVID-19 must counterbalance the risk for infection to the infant with the known health benefits of close contact and breastfeeding to the infant and mother; yet, different organizations, countries, and experts vary in how they calculate this balance, which is challenging, given gaps in knowledge concerning SARS-CoV-2 transmission.
In Wuhan, China, the original epicenter of the pandemic, current protocol leans toward the side of caution, with mother-infant separation and discouraging breastfeeding until the mother is deemed no longer infectious. In Italy, the pendulum swings toward rooming-in of the mother with COVID-19 and her infant, with European Union (EU) professional societies endorsing these guidelines.
Citing the benefits of breastfeeding for the infant, mother, and global public health, the World Health Organization (WHO) tends to side with the EU whereas the Centers for Disease Control and Prevention (CDC) currently seems to favor the Asian approach. Despite their contrasting views, all these organizations acknowledge at least some role of the mother’s informed choice and offer strategies to mitigate the risk for infant infection when mothers with COVID-19 opt for breastfeeding.
China Recommends Infant Isolation
According to their experience with clinical management for pregnant women and newborns with COVID-19 pneumonia, Tongji Hospital, in Wuhan, China, has revised their proposed guidelines for care of such patients.[1] This guidance addresses mode of mother-to-child transmission, management of postpartum fever, neonatal isolation, and breastfeeding.
Possible modes of SARS-CoV-2 transmission from mother to newborn include vertical transmission from mother to fetus, close contact transmission, droplet transmission from family or visitors, and hospital-acquired infections. Newborns with potential exposure should be isolated, monitored, and tested for SARS-CoV-2 using nucleic acid testing.
Most reports to date suggest lack of evidence for vertical transmission of SARS-CoV-2 but acknowledge that no definitive conclusions can yet be drawn. In contrast, however, Wang and colleagues wrote, "It has been reported that a case of SARS-CoV-2 infection with positive nucleic acid of pharyngeal swab virus occurred in a baby only 36 [hours] after birth, and the mother was a confirmed case of SARS-CoV-2 infection. Therefore, the existence of mother-to-child transmission of SARS-CoV-2 remains to be verified. In addition, breastfeeding should not be performed if the mother was infected by SARS-CoV-2."
Tongji Hospital also mandates that newborns confirmed to be infected with SARS-CoV-2 be kept in an isolated observation ward for at least 14 days and that persons with suspected infection should be transferred to an isolation ward for observation or treatment until the recovery standard is met. Rooming-in of mother and infant in the same room is permitted only when the mother has 2 consecutive negative SARS-CoV-2 nucleic acid tests, 1 day apart, and only with informed consent.
Other recommendations from Tongji Hospital are to clean newborns as soon as possible; to examine mothers for postpartum fever and to test persons with COVID-19 symptoms for evidence of SARS-CoV-2 infection; to defer completion of newborn disease screening and hearing testing until "after the end of the epidemic"; and to discourage breastfeeding in "suspected cases, uncured clinically diagnosed cases and uncured confirmed cases."
Factors underlying these stringent recommendations include evidence that even asymptomatic persons may be infected with SARS-CoV-2 and spread it to others. In addition, some antiviral agents used in China, such as lopinavir and ritonavir, can be secreted in rat milk, but it is uncertain whether secretion into breast milk occurs in women taking these drugs.
Italy, EU More Lenient
In contrast, interim indications regarding breastfeeding and COVID-2019 issued by the Italian Society of Neonatology and endorsed by the Union of European Neonatal & Perinatal Societies[2] call for a more lenient approach, pending further evidence.
"Besides the possible consequences of COVID-19 infection on a pregnant woman and the fetus, a major concern is related to the potential effect on neonatal outcome, the appropriate management of the mother-newborn dyad and finally the compatibility of maternal COVID-19 infection with breastfeeding," the authors wrote.
If a mother who is COVID-19--positive or who is a person under investigation (PUI) for COVID-19 is asymptomatic or has few symptoms at delivery, rooming in is feasible and direct breastfeeding is advisable but with strict infection control measures.
"On the contrary, when a mother with COVID-19 is too sick to care for the newborn, the neonate will be managed separately and fed fresh expressed breast milk, with no need to pasteurize it, as human milk is not believed to be a vehicle of COVID-19," the authors concluded.
Could Donor Milk Banking Help Fill the Gap?
An international perspective[3] cited the many benefits of breast milk to the newborn and lamented the effect of the COVID-19 pandemic on donor milk banking, which could fill the gap in situations where infected mothers are unable to breastfeed.
"Donor milk banking is predicated always on the protection, promotion and support of breastfeeding," wrote Kathleen A. Marinelli, MD. "We believe this deadly virus is not transmitted through mother’s milk. We do not know if there is vertical transmission or not."
She noted that newborns may be a high-risk group for COVID-19, as they are for other viral infection. Although the present lack of herd immunity against SARS-CoV-2 reduces the likelihood of specific immune factors against it in human milk, one mother with severe acute respiratory syndrome (SARS) was shown to have anti-SARS-CoV antibody in her postpartum milk.
“[A]s we know, there are so many immune factors in, and immune functions of, human milk, that its provision to our youngest and very vulnerable must continue to be of paramount importance,” Marinelli wrote.
The perspective reviewed available evidence to date. In a Wuhan case series of 9 pregnant women with COVID-19 in January 2020, 6 mothers were tested and all samples were negative for SARS-CoV-2 in amniotic fluid, cord blood, neonatal throat swabs, and milk samples.
“The ability to provide support and to protect our breastfeeding mothers becomes extremely difficult where the virus is rampant,” Marinelli concluded. “If we cannot support breastfeeding, how will we ensure a supply of donor milk? In populations with large areas under quarantine or “lockdown,” how are we to move “safe” milk from the donors to the milk banks? In the bigger picture, what does this mean for the health of our children, as we may in fact see breastfeeding rates, and the supply and use of donor milk, decrease during this very unstable and concerning of times."